.jpg)
STAT+: Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer
Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.
Gilead Sciences said Monday that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.
The results from a randomized Phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed, metastatic, triple-negative breast cancer. Gilead could also benefit from a boost in Trodelvy sales at a time when it faces competition from a similar drug made by AstraZeneca and Daiichi Sankyo.
In the study, the combination of Trodelvy and Keytruda demonstrated a “clinically meaningful” improvement in progression-free survival compared to Keytruda plus chemotherapy — achieving the study’s primary efficacy goal, Gilead said.
